ucsf logo

New ways to tackle cancer-causing virus, eye disease win CTSI funding awards

A promising new way to fight human herpes viruses and a drug delivery device to better treat a major cause of blindness have won development funding from UCSF’s Clinical and Translational Science Institute (CTSI).

The herpes virus treatment project, awarded $100,000 under CTSI’s T1 Translational Catalyst Awards, is led by Charles Craik, PhD, a faculty member in the UCSF School of Pharmacy’s Department of Pharmaceutical Chemistry. One of the project’s prime targets is the virus that causes the most common HIV/AIDS-associated cancer.

The development of the device to treat eye disease, which was awarded $85,000, is led by Tejal Desai, PhD, a faculty member in the Department of Bioengineering and Therapeutic Sciences, a joint department of the UCSF Schools of Pharmacy and Medicine.

The T1 Awards, which are offered twice a year, are designed to help drive promising early-stage research through the process of translating ideas into therapies that benefit patients. In addition to funding, they provide customized expert feedback and advice.


Clinical and Translational Science Institute
Translational Catalyst Awards
herpes virus
drug delivery device
dimer disrupter 2
allosteric regulation
Kaposi’s sarcoma-associated herpes virus
Small Molecule Discovery Center
age-related macular degeneration
National Eye Institute
National Institutes of Health
Key people: 
Charles S. Craik
Tejal Desai
Adam Renslo
Jonathan Gable
Gregory Lee

Next topic: About QBC